Multidrug resistance Acinetobacter species in ventilator associated pneumonia patients in MICU
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242939Keywords:
Acinetobacter spp., Multidrug resistant, Minocycline, Ventilator associated pneumoniaAbstract
Background: Ventilator associated pneumonia (VAP) is defined as pneumonia that develops 48-72 hours after endotracheal intubation and is characterized by the presence of a new or progressive infiltrate, symptoms of systemic infection, respiratory distress, and the microbiological discovery of a causal agent. There is a substantial attributable death rate linked to VAP caused by Acinetobacter species.
Methods: A hospital-based retrospective study was conducted from June 2023 to June 2024 at GMCH, Aurangabad. Six hundred thirteen (613) endotracheal aspirate samples were obtained from patients admitted in intensive care unit. Semi-quantitative processing of the samples was done using accepted microbiological methods. According to CLSI guidelines, antimicrobial susceptibility testing was done.
Results: Out of 613 samples, organism isolated were Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, and Enterobacter cloacae. Thirty-seven (37) VAP cases were found from 613 samples; sixteen (16) of them (43%) developed VAP as a result of multidrug resistant (MDR) Acinetobacter baumannii. Eleven (69%) of the sixteen VAP cases exhibited minocycline sensitivity. Nine out of 16 VAP cases (56%) had a fatal outcome as a result of the MDR Acinetobacter species.
Conclusions: According to this study, minocycline is the most effective drug against MDR Acinetobacter species. To lower mortality and morbidity in VAP patients, it is important to identify the organism and follow IPC procedures, which include hand hygiene techniques, bundle care approach, disinfections, screening of the patient's environment, development of an antimicrobial stewardship program, and frequent surveillance.
References
Shete VB, Ghadage DP, Muley VA, Bhore AV. Multi-drug-resistant Acinetobacter ventilator-associated pneumonia. Lung India. 2010;2.
Bishwas A, Shenoy P. Microbial profile of ventilator associated pneumonia in a medical intensive care unit of a tertiary care hospital in Bangalore. J Evol Med Dent Sci. 2020;9(19):1539-44.
Alotaibi T, Abuhaimed A, Alshahrani M, Albdelhady A, Almubarak Y, Almasari O. Prevalence of multidrug-resistant Acinetobacter baumannii in a critical care setting: A tertiary teaching hospital experience. SAGE Open Med. 2021;9:20503121211001144.
Huang Y, Zhou Q, Wang W, Huang Q, Liao J, Li J, et al. Acinetobacter baumannii ventilator-associated pneumonia: clinical efficacy of combined antimicrobial therapy and in vitro drug sensitivity test results. Front Pharmacol. 2019;10:92.
Salehi M, Jafari S, Ghafouri L, Malekafzali Ardakani H, Abdollahi A, Beigmohammadi MT, et al. Ventilator-associated pneumonia: multidrug resistant Acinetobacter versus extended spectrum beta lactamase-producing Klebsiella. J Infect Dev Ctries. 2020;14(6):660-3.
Golia S, Sangeetha KT, Vasudha CL. Microbial profile of early and late onset ventilator associated pneumonia in the intensive care unit of a tertiary care hospital in Bangalore, India. J Clin Diagn Res. 2013;7(11):2462.
Dey A, Bairy I. Incidence of multidrug-resistant organisms causing ventilator-associated pneumonia in a tertiary care hospital: a nine months' prospective study. Ann Thorac Med. 2007;2(2):52-7.
Segatore B, Piccirilli A, Cherubini S, Principe L, Alloggia G, Mezzatesta ML, et al. In Vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii clinical isolates: a multicentre report from Italy. Antibiotics. 2022;11(8):1136.
Čiginskienė A, Dambrauskienė A, Rello J, Adukauskienė D. Ventilator-associated pneumonia due to drug-resistant Acinetobacter baumannii: risk factors and mortality relation with resistance profiles, and independent predictors of in-hospital mortality. Medicina. 2019;55(2):49.
Baraibar J, Correa H, Mariscal D, Gallego M, Valles J, Rello J. Risk factors for infection by Acinetobacter baumannii in intubated patients with nosocomial pneumonia. Chest. 1997;112:1050-4.
Moubareck CA, Halat DH. Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics (Basel). 2020;9(3):119.
Semet C. The ongoing challenge of ventilator-associated pneumonia: epidemiology, prevention, and risk factors for mortality in a secondary care hospital intensive care unit. Infect Prevent Pract. 2023;5(4):100320
Chaari A, Mnif B, Bahloul M, Mahjoubi F, Chtara K, Turki O, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. Int J Infect Dis. 2013;17(12):e1225-8.
Mathai AS, Oberoi A, Madhavan S, Kaur P. Acinetobacter infections in a tertiary level intensive care unit in northern India: epidemiology, clinical profiles and outcomes. J Infect Public Health. 2012;5(2):145-52.
